Our findings suggest UGT1A1 polymorphisms may be useful to screen the risk population of gastric cancer and schedule the appropriate pretreatment to improve the overall survival, while TYMS, TUBB3 and STMN1 may be potential biomarkers for prognosis and chemotherapy guidance. The gene discussed is UGT1A1; the disease is gastric cancer.